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Background: The role of fomites and the environment in nosocomial infections is becoming widely recognized. In
this paper we discuss the use of Cupron copper oxide impregnated non-porous solid surface in the hospital setting
and present in vitro testing data via USA Environmental Protection Agency (EPA) approved testing protocols that
demonstrate the efficacy of these products to assist in reduction in environmental contamination and potentially
nosocomial infections.
Results: The two countertops tested passed all the acceptance criteria by the EPA (>99.9% kill within 2 hours of
exposure) killing a range of bacterial pathogens on the surface of the countertops even after repeated exposure of
the countertops to the pathogen, and multiple wet and dry abrasion cycles.
Conclusions: Cupron enhanced EOS countertops thus may be an important adjunct to be used in hospital settings
to reduce environmental bioburden and potentially nosocomial infections.
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Hospital Acquired Infections (HAI) have exacted a heavy
toll worldwide with over 2 million patients annually con-
tracting an infection in the US [1], being one of the lead-
ing causes of death in the US behind cancer and strokes
[2]. In Europe, out of 3 million HAI [3] approximately
50,000 resulted in death [4], and in Australia more than
177,000 HAI occur per year [5] whilst in the province of
Quebec, Canada the rate of HAI are estimated to be
around 11% [6]. The HAI rates in developing countries are
significantly higher [7-9]. According to the USA Center for
Disease Control (CDC) some of the predominant HAI
organisms are Staphylococcus aureus, Pseudomonas aeru-
ginosa, and Enterobacter species [10]. Methicillin resistant
S. aureus accounts for 50% of HAI associated with multi-
drug resistant pathogens [10]. The Extended Prevalence
of Infection in Intensive Care (EPIC II) study demon-
strated a 50% HAI rate in ICU patients sampled from
over 75 countries and two of the most predominant or-
ganisms were resistant Staphylococci and P. aeruginosa
[11]. HAI are associated with considerable mortality,
morbidity and costs [2,12]. Recent intervention efforts* Correspondence: amonk@cupron.com
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unless otherwise stated.including improvement of national surveillance, use of ag-
gressive antibiotic control programs, healthcare staff edu-
cation for improved hygiene, isolation of infected patients,
use of disposable equipment, cleaning and disinfection of
environmental surfaces and equipment, improvement of
cleaning equipment and sanitary facilities, increase in
nursing and janitorial resources and better nutrition
[13-17], have been shown to reduce HAI rates. However
further supplemental interventions are required. The link
between contaminated hard surfaces to HAI has been
demonstrated [18-28] and an antimicrobial protected
touch surface would assist in reduction of pathogen
buildup upon touch surfaces as long as that activity can be
indisputably demonstrated.
Thus, our objective was to demonstrate the efficacy of
two solid surface countertops incorporating copper (I)
oxide in killing a range of pathogens according to protocols




The following bacterial strains were tested: Staphylococ-
cus aureus (ATCC 6538); Enterobacter aerogenes (ATCC
13048); Pseudomonas aeruginosa (ATCC 15442); Methicillintd. This is an Open Access article distributed under the terms of the Creative
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http://www.biomedcentral.com/1471-2180/14/57resistant Staphylococcus aureus (MRSA)(ATCC 33592);
and Escherichia coli 0157:H7 (ATCC 35150).
Materials
The studied countertops were composed of homogenous
blends of polyester, acrylic alloys and fillers, inert pig-
ment and dyes, with (test samples) or without (control
samples) Cupron’s 16% copper (I) oxide weight/weight.
Three and two separate manufacturing lots of the test
and control countertop samples were tested, respect-
ively. A total of 1500 pieces, cut into one inch by one
inch squares (Figure 1), 300 per each manufacturing lot,
were tested. The countertops were examined by Scanning
Electron Microscopy (SEM) and Energy-dispersive X-ray
spectroscopy (EDS) by using Hitachi FE-SEM SU-70. The
Cupron Enhanced EOS Surface is a novel polymeric solid
surface that has all the properties of a solid surface includ-
ing hardness, firmness, and the ability to be easily cleaned




Figure 1 SEM pictures and EDS analysis of a representative counterto
tested countertop impregnated with copper oxide; B. A SEM imaging of th
imaging of the Countertop (purple dots indicating the copper oxide); D. cu
copper oxide particles); and E. corresponding EDS spectra of D, showing acopper. The surface can be easily refinished and repaired
in the event of damage or aesthetic appeal. The surfaces
are currently available in two color choices due to the
addition of pigments to alter the color of the surfaces at
the time of manufacture. The surface is produced by mix-
ing a blend of acrylic and polyester resins with copper
oxide and pigments, which is then heated until liquified
and poured into casting molds. The material is allowed to
cure allowing the polymerization of the material to pro-
duce a solid surface which can then be cut and shaped to
produce a final product or installed surface.Biocidal testing protocols
The biocidal testing of the countertops was conducted
by an independent laboratory, MicroBiotest, a division of
Microbac Laboratories, Inc. Sterling, VA, using Good
Laboratory Practice (GLP) according to protocols pre-







p containing copper oxide particles. A. A representative picture of a
e Countertop (white dots indicating copper oxide particles; C. EDS
t through SEM imaging of the Countertop (white dots indicating
peak corresponding to copper.
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The carriers were cleaned with 70% isopropyl alcohol,
rinsed with deionized water, and allowed to air dry. After
steam sterilization for 15 minutes at 121°C, each carrier
was placed into a plastic Petri dish matted with two
pieces of filter paper using sterile forceps. Two or three
lots of manufacturing of each test material were tested
per microorganism. Five replicates of each material were
used in each test. Organisms from stock cultures were
transferred to Tryptic Soy Broth and incubated for 24
hours at 35-37°C (25-30°C for ATCC 13048). Two loop-
fuls of culture were transferred consecutively daily for
three days for the inoculation stocks and the pellicle of
bacteria were aspirated. Daily transfers were done for at
least 3 consecutive days but for no more than 10 days.
To this culture 0.25 ml of heat-inactivated fetal bovine
serum (FBS) and 0.05 ml of Triton X-100 were added to
4.7 ml bacteria suspension to yield 5% FBS and 0.01%
Triton X-100 organic soil load. The challenge micro-
organism titer was determined by serially diluting a final
48 hour culture using phosphate buffered solution (PBS)
and selected dilutions were plated in duplicate using
Tryptic Soy Agar (TSA) pour plates. Carriers were inoc-
ulated with 0.02 ml of the 48 hour culture. The bacterial
inoculum per experiment is detailed in Table 1. All con-
trol plates were incubated in parallel to the test plates.
The inoculum was spread to within ~1/8 inch of the
control or test carrier before air drying for 20–40 mi-
nutes at 35-37°C and 38-42% relative humidity. After
120 minutes exposure at 21°C, the carriers were trans-
ferred to 20 ml neutralizer solution (2x Letheen broth
[29]) and sonicated for 5 minutes and rotated to mix.
Within one hour serial dilutions (10−1 to 10−4) were
made in PBS and plated using TSA and incubated for 48
hours at 35-37°C for colony observation and enumer-
ation, taking into account also the 20 fold dilution used
to retrieve the bacteria from the carriers. The following
controls were performed: culture purity control - each
prepared culture was streaked using TSA for purity con-
trol; organic soil purity control - duplicate 1 ml aliquots
of organic soil were plated in TSA pour plates for steril-
ity control; neutralizer sterility control – a jar containing
the neutralizer was incubated with the test plates and
observed for growth or no growth; carrier sterility con-
trol – an uninoculated test (per lot) and control carrier
was put in independent jars containing the neutralizer,
incubated and observed for growth or no growth; carrier
viability control – for each challenge microorganism, a
single inoculated control carrier was subcultured in a jar
containing the neutralizer, incubated and the neutralizer
observed for growth or no growth; and neutralization
confirmation control – for each challenge microorgan-
isms, per lot of the test article, a single sterile test carrier
was put in individuals jars containing 20 ml of theneutralizer. To each jar a 1 ml aliquot of the diluted in-
oculum was added to reach ~100 colony forming units
(CFU)/ml in the neutralizer. The jar was mixed and the
1 ml inoculum was removed and plated in duplicate.
Protocol 2- residual sanitizer activity
A sanitization test was followed as described above
(Protocol 1) using 4 replicates per material. Post this ini-
tial test a Gardner apparatus was used to simulate sur-
face wear of the test and control samples. The abrasion
tester was used at a speed of 2.25 to 2.5 for a total con-
tact time of 4–5 seconds for one complete cycle. A wear
cycle equals one pass to the left and a return pass to the
right. After a minimum of 15 minutes after the wear
cycle each carrier was reinoculated as described above
and dried for a minimum of 30 minutes. After each set
of surface wear, absolute ethanol was used to sterilize
the apparatus and the foam liner and cotton cloth were
changed after each wear test. Wet cycles and dry cycles
were alternated and for wet wear cycles the boat assem-
bly included a new foam liner and dry cotton cloth
sprayed with sterile deionized water using a preval
sprayer from a distance of 75±1 cm for not more than
one second. At least 24 hours passed between the initial
inoculation and final sanitizer. Overall 12 wear cycles
were completed before sanitizer activity was assessed
using the method outlined above. All the controls as
outlined for Protocol 1 were performed.
Protocol 3- continuous bacterial reduction
A sanitization test was followed as described above
(Protocol 1) using 5 replicates per each material tested.
The carriers were consecutively inoculated for 8 times
by adding the challenge microorganism at 0, 3, 6, 9, 12,
15, 18 and 21 hours. Efficacy was assessed at 2, 6, 12, 18
and 24 hours, which corresponds to 1, 2, 4, 6, and 8 in-
oculations. After exposure the carriers were transferred
to a neutralizer solution and sonicated and rotated to
mix. Within one hour, serial dilutions (10−1 to 10−4)
were spread on plates using appropriate media and incu-
bated for 48 hours for colony observation and enumer-
ation. All the controls as outlined for Protocol 1 were
performed.
Results
The challenge microorganisms were confirmed for pur-
ity by Gram stain and colony morphology. Controls
demonstrated that the organic soil, carrier and neutraliz-
ing medium were sterile. The neutralizing solution itself
did not show any bacterial inhibition. The bacterial titers
(actual CFU after taking into consideration the relevant
dilutions) recovered from the control samples following
the different protocols, which included air drying, sonic-
ation, and recovering the bacteria from the exposed
Table 1 CFU recovered from control samples
Microorganism Protocol Replicate Inoculum Titers recovered Average
CFU/carrier CFU/carrier CFU/carrier
S. aureus 1 1 0.22 × 108 8.4 × 105 7.5 × 105
2 7.0 × 105
3 7.2 × 105
2 - initial 1 0.42 × 108 1.1 × 106 1.3 × 106
2 1.6 × 106
3 1.2 × 106
4 1.3 × 106
2 - Final 1 0.46 × 108 9.9 × 105 1.1 × 106
2 1.1 × 106
3 1.3 × 106
4 1.0 × 106
3 - 2 hours 1 0.38 × 108 8.2 × 105 9.3 × 105
2 1.0 × 106
3 9.4 × 105
3 - 6 hours 1 2.0 × 106 1.8 × 106
2 1.8 × 106
3 1.7 × 106
3 - 12 hours 1 2.5 × 106 2.5 × 106
2 2.4 × 106
3 3.7 × 106
3 - 18 hours 1 3.7 × 106 3.6 × 106
2 3.6 × 106
3 3.5 × 106
3 - 24 hours 1 4.6 × 106 4.6 × 106
2 4.6 × 106
3 4.5 × 106
E. aerogenes 1 1 0.38 × 109 7.4 × 106 7.9 x106
2 8.8 × 106
3 7.6 × 106
2 - initial 1 0.22 × 109 1.1 × 106 1.1 × 106
2 1.0 × 106
3 1.2 × 106
4 1.1 × 106
2 - Final 1 0.4 × 109 1.5 × 106 1.2 × 106
2 1.4 × 106
3 8.3 × 105
4 1.1 × 106
3 - 2 hours 1 0.38 × 109 2.0 × 106 2.0 × 106
2 2.1 × 106
3 2.0 × 106
3 - 6 hours 1 3.8 × 106 3.9 × 106
2 3.9 × 106
3 3.9 × 106
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Table 1 CFU recovered from control samples (Continued)
3 - 12 hours 1 5.1 × 106 4.7 × 106
2 5.4 × 106
3 3.6 × 106
3 - 18 hours 1 4.8 × 106 5.6 × 106
2 6.8 × 106
3 5.2 × 106
3 - 24 hours 1 8.5 × 106 7.9 × 106
2 8.4 × 106
3 6.8 × 106
MRSA 1 1 0.38 × 109 7.4 × 105 8.5 × 105
2 9.8 × 105
3 8.2 × 105
2 - initial 1 0.36 × 108 7.3 × 105 7.5 × 105
2 9.5 × 105
3 6.6 × 105
4 6.5 × 105
2 - Final 1 0.32 × 108 5.6 × 105 6.9 × 105
2 5.7 × 105
3 8.0 × 105
4 8.2 × 105
3 - 2 hours 1 0.26 × 108 4.0 × 105 4.0 × 105
2 3.8 × 105
3 4.2 × 105
3 - 6 hours 1 8.6 × 105 8.8 × 105
2 9.8 × 105
3 7.9 × 105
3 - 12 hours 1 9.9 × 105 1.0 × 106
2 1.2 × 106
3 9.1 × 105
3 - 18 hours 1 1.8 × 106 1.7 × 106
2 1.6 × 106
3 1.7 × 106
3 - 24 hours 1 1.8 × 106 1.8 × 106
2 1.8 × 106
3 1.7 × 106
P. aeruginosa 1 1 0.2 × 108 6.8 × 106 7.0 × 106
2 7.4 × 106
3 6.9 × 106
2 - initial 1 0.2 × 109 1.0 × 106 1.3 × 106
2 1.4 × 106
3 1.4 × 106
4 1.5 × 106
2 - Final 1 0.34 × 109 2.4 × 106 2.0 × 106
2 1.9 × 106
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Table 1 CFU recovered from control samples (Continued)
3 1.6 × 106
4 2.0 × 106
3 - 2 hours 1 0.3 × 109 2.6 × 105 2.5 × 105
2 2.5 × 105
3 2.5 × 105
3 - 6 hours 1 5.2 × 105 5.2 × 105
2 5.3 × 105
3 5.3 × 105
3 - 12 hours 1 7.2 × 105 7.2 × 105
2 7.1 × 105
3 7.4 × 105
3 - 18 hours 1 9.8 × 105 9.6 × 105
2 9.5 × 105
3 9.6 × 105
3 - 24 hours 1 9.8 × 105 9.7 × 105
2 9.2 × 105
3 1.0 × 106
E. coli O157:H7 1 1 0.36 × 109 6.4 × 106 6.6 × 106
2 6.7 × 106
3 6.6 × 106
2 - initial 1 0.24 × 109 1.5 × 106 1.1 × 106
2 8.3 × 106
3 1.1 × 106
4 1.1 × 106
2 - Final 1 0.22 × 109 7.8 × 105 9.4 × 105
2 8.0 × 105
3 1.2 × 106
4 9.9 × 105
3 - 2 hours 1 0.36 × 109 2.5 × 105 2.6 × 105
2 2.6 × 105
3 2.7 × 105
3 - 6 hours 1 5.2 × 105 5.3 × 105
2 5.2 × 105
3 5.4 × 105
3 - 12 hours 1 7.9 × 105 7.7 × 105
2 7.7 × 105
3 7.6 × 105
3 - 18 hours 1 1.0 × 106 1.0 × 106
2 1.1 × 106
3 1.0 × 106
3 - 24 hours 1 1.2 × 106 1.2 × 106
2 1.2 × 106
3 1.2 × 106
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show the bacterial titers recovered from the Test sam-
ples following the various protocols and the percent re-
duction in the bacterial titers recovered as compared to
the mean bacterial titers recovered from the control
samples. All experiments conducted with the copper
oxide impregnated countertops demonstrated over a 3
log (>99.9%) reduction against all organisms tested, as
compared to the control countertops without copper
(Tables 2, 3 and 4). Out of the 192 data points obtained
(average of 4 or 5 replicates each) for the test counter-
tops, there were only two exceptions for the continuous
sanitizer activity test - with a 99.8% and 99.2% reduc-
tions against Pseudomonas aeruginosa (Table 4), which
exceeds the 99% reduction requirement set up by the
EPA for continuous efficacy kill rates. As determined
by SEM and EDS analysis, copper oxide particles are
homogenously distributed within (Figure 1D and E) and
throughout the surface (Figure 1B and C) of the test
countertops.Table 2 Results from Protocol 1- Sanitizer Activity
Countertop Organism CFU/ Recovered from control sample
Test 1
S. aureus 7.5 × 105
E. aerogenes 7.9 × 106
MRSA 8.5 × 105
P. aeruginosa 7 × 106
E. coli 0157:H7 6.6 × 106
Test 2
S. aureus 7.5 × 105
E. aerogenes 7.9 × 106
MRSA 8.5 × 105
P. aeruginosa 7.0 × 106
E. coli 0157:H7 6.6 × 106
*Values taken from Table 1.
**Compared to control, each number represents an average of 5 replicates per manDiscussion
Bacteria can persist on inanimate surfaces for months
[30] and can be a potential source for outbreaks of noso-
comial infections [18,19,27]. Thus using self-sanitizing
surfaces can be a very important adjunct in the fight
against nosocomial pathogens [31]. The data collected
under GLP independent testing using a predefined con-
centration of cultivated ATCC referenced bacterial
strains, demonstrated the antimicrobial properties of
Cupron copper oxide impregnated countertops. Protocol
number 1 tested the capacity of copper oxide infused
countertops to kill a number of cultivated pathogens
(Table 2) under conditions prescribed by the US EPA for
the in vitro testing of the antimicrobial efficacy of copper
oxide particles suspended in a plastic matrix. The organ-
isms tested constitute a broad representation of current
HAI organisms, and with over a three log reduction
(>99.9%) achieved within 2 hours of exposure the authors
conclude that these copper oxide infused countertops

























ufacturing lot. Either 2 or 3 lots were examined per organism.
Table 3 Results from protocol 2- residual sanitizer efficacy
Countertop Organism CFU recovered from control samples* Lot CFU recovered from test samples % reduction**
Test 1- Initial








MRSA 7.5 × 105
1 <1.5;<1.5;<1.5;<1.5 >99.9
2 <1.5;<1.5;<1.5;<1.5 >99.9
P. aeruginosa 1.3 × 106
1 <1.5;<1.5;<1.5;<1.5 >99.9
2 <1.5;<1.5;<1.5;90 >99.9






























MRSA 7.6 × 105
1 <1.5;<1.5;<1.5;<1.5 >99.9
2 <1.5;<1.5;<1.5;<1.5 >99.9
P. aeruginosa 1.3 × 106
1 150;<1.5;9;230 >99.9
2 450;570;<1.5;<1.5 >99.9












MRSA 6.9 × 105
1 <1.5;<1.5;<1.5;<1.5 >99.9
2 <1.5;<1.5;<1.5;<1.5 >99.9
Monk et al. BMC Microbiology 2014, 14:57 Page 8 of 14
http://www.biomedcentral.com/1471-2180/14/57
Table 3 Results from protocol 2- residual sanitizer efficacy (Continued)
P. aeruginosa 2.0 × 106
1 <1.5;<1.5;<1.5;<1.5 >99.9
2 <1.5;<1.5;<1.5;<1.5 >99.9
E. coli 0157:H7 9.4 × 105
1 <1.5;<1.5;<1.5;<1.5 >99.9
2 <1.5;<1.5;<1.5;<1.5 >99.9
*Values taken from Table 1.
**Compared to control, each number represents an average of 4 replicates per manufacturing lot. Either 2 or 3 lots were examined per organism.
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as demonstrated by using Protocol 2, simulating pro-
longed surface wear, the countertops continue to be
highly efficacious even after 12 consecutive wet and dry
wear and inoculation cycles (Table 3), simulating sur-
face abrasion that occurs due to cleaning and use. Des-
pite the erosion of the countertops’ surface, there was
no reduction in biocidal efficacy. This is explained by
the distribution of the copper oxide particles through-
out the matrix, on and within the surface (Figure 1),
and the appearance of “new” particles on the surface
as the countertop surface is eroded. This property of
the countertops practically endows them with biocidal
properties for the life of the product. Protocol 3 dem-
onstrated that the countertops are efficacious to con-
secutive bacterial inoculations (Table 4) in the same
exact spot, indicating that the countertops do not lose
their biocidal efficacy following bacterial kill, but main-
tain this biocidal property continuously.
Copper has a long history as an antimicrobial and pre-
ventative measure and metallic copper countertops have
previously been approved for EPA public health claims
[32]. Field trials of these countertops have demonstrated
the reduction in bioburden in a variety of clinical settings
[33-37] and a reduction in the risk of infections [38,39].
Based on the data presented in this publication, Cupron
Enhanced EOS Surfaces infused with copper have been
approved for public health claims relating to their anti
bacterial efficacy. Some of the approved health claims are
a) “This surface continuously reduces bacterial* contamin-
ation achieving a 99.9% reduction within two hours of ex-
posure.”; b) “This surface kills greater than 99.9% of Gram
negative and Gram positive bacteria* within two hours
of exposure.”; c) “This surface kills greater than 99.9%
of bacteria* within two hours and continues to kill 99% of
bacteria* even after repeated contamination.”; and d) “This
surface helps inhibit the buildup and growth of bacteria*
within two hours of exposure between routine cleaning
and sanitizing steps”. *Testing demonstrates effective anti-
bacterial activity against Staphylococcus aureus (ATCC
6538), Enterobacter aerogenes (ATCC 13048), MRSA
(ATCC 33592), Escherichia coli O157:H7 (ATCC 35150)
and Pseudomonas aeruginosa (ATCC 15442).
These non-porous Cupron copper oxide containing
solid surfaces possess comparable efficacy to the metallichard surfaces, however represent a much more feasible
alternative to the metallic surfaces as they are expected
to be significantly more affordable and aesthetically
more pleasing. Field trials are ongoing at the time of
publication to demonstrate the efficacy of these counter-
tops in a “real world” setting (Borkow and Monk, un-
published). The biocidal properties of copper oxide
against a range of organisms have also been previously
demonstrated [40-43].
Limitations of this study include that the data is based
upon ATCC laboratory strains and conducted in a con-
trolled setting such as a laboratory, however further
work is ongoing utilizing field trials of the surface to
demonstrate the efficacy in real world applications.
Bacterial resistance to biocidal control agents is of
concern in infection prevention and can be exemplified
by highly antibiotic resistant bacteria (with up to 2200-
fold decreased sensitivity to the antibiotic (e.g. [44]) that
have evolved in less than 50 years of antibiotic usage,
making infected patient treatment extremely difficult (e.g.
[45]). Consequently, the possibility of development of
resistance to biocides is a real concern [46,47]. Import-
antly, as opposed to antibiotics, despite evolving in the
continued presence of copper, no microorganisms that
are highly resistant to copper have been found, but only
microorganisms with increased copper tolerance [31].
Importantly, no resistant bacteria evolved in vitro when
repeatedly and consecutively exposed to fabrics contain-
ing copper oxide particles [42]. The reason why no re-
sistance to copper is found in microorganisms exposed to
constant relatively high doses of copper, is because copper
exerts its biocidal/antimicrobial activity not through one
mechanism (as most antibiotics), but through several
parallel non-specific mechanisms [48,49]. Both metallic
copper and copper oxide particles, in the presence of hu-
midity, even that present in air, release copper ions. The
released copper ions can migrate and reach the microor-
ganisms even though they may not be in direct contact
with the copper oxide particles. These ions can cause
plasma membrane permeabilization, membrane lipid per-
oxidation, alteration of proteins and inhibition of their
biological assembly and activity, and denaturation of nu-
cleic acids [48,49]. It is likely that the first site that copper
ions damage is the microorganisms’ envelope via electro-
static forces [50], altering the membrane integrity and
Table 4 Results from protocol 3- continuous self sanitizing activity
Countertop Organism CFU recovered from control samples Lot CFU recovered from test samples % reduction**
Test 1–2 hours








MRSA 4.0 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
P. aeruginosa 2.5 × 105
1 480;370;480;180;120 99.9
2 420;480;240;450;360 99.8












MRSA 8.8 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
P. aeruginosa 5.2 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;170;<1;<1;<1 >99.9












MRSA 1.0 × 106
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
P. aeruginosa 7.2 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9












MRSA 1.7 × 106
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
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Table 4 Results from protocol 3- continuous self sanitizing activity (Continued)
P. aeruginosa 9.6 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9












MRSA 1.8 × 106
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
P. aeruginosa 9.7 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9












MRSA 4.0 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
P. aeruginosa 2.5 × 105
1 260;200;540;200;400 99.9
2 200;410;560;280;680 99.2












MRSA 8.8 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
P. aeruginosa 5.2 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
E. coli 0157:H7 5.3 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
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Table 4 Results from protocol 3- continuous self sanitizing activity (Continued)




MRSA 1.0 × 106
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
P. aeruginosa 7.2 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9












MRSA 1.7 × 106
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
P. aeruginosa 9.6 × 105
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9












MRSA 1.8 × 106
1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
P. aeruginosa 9.7 × 105 1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
E. coli 0157:H7 1.2 × 106 1 <1;<1;<1;<1;<1 >99.9
2 <1;<1;<1;<1;<1 >99.9
*Values taken from Table 1.
**Compared to control, each number represents an average of 5 replicates per manufacturing lot. Either 2 or 3 lots were examined per organism.
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formational changes in the structure of intracellular or
membrane proteins or in the proteins active site also by
direct interaction or by displacing essential metals from
their native binding sites in the proteins (e.g. [53,54]).
Furthermore, the redox cycling between Cu2+ and Cu1+,
which can catalyze the production of highly reactive
hydroxyl radicals, can subsequently damage lipids, pro-
teins, DNA and other biomolecules [48,55]. In addition,
metallic copper, as well as cuprous oxide particles,
in the absence of humidity, cause massive membranedamage and kill microorganisms within minutes via
direct “contact killing” [56-58]. Apparently, the metal-
bacterial contact damages the cell envelope, which, in
turn, makes the cells susceptible to further damage by
copper ions [58].
Microorganisms cannot cope when exposed to high
concentrations of copper and are irreversibly damaged,
as demonstrated also in this study. Thus, the develop-
ment of resistant bacteria to copper due to the intro-
duction of the copper containing countertops to the
hospital environment is not a concern.
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http://www.biomedcentral.com/1471-2180/14/57With the ongoing HAI problem and the role of fomites
and the environment being more clearly defined, the role
of antimicrobial products with EPA approved public health
claims, above and beyond the treated article claims and
with clinical data supporting their role in HAI prevention,
will become more important.
Conclusion
The tested Cupron Enhanced EOS Surfaces containing
copper oxide kill above 99.9% of a wide range of bacteria
within two hours of exposure and continue to do so even
after repeated contamination and multiple wet and dry
abrasion cycles, passing all the acceptance criteria required
by the EPA. These biocidal surfaces thus may be an import-
ant adjunct to be used in hospital settings to reduce envir-
onmental bioburden and potentially nosocomial infections.
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